Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
HS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies MONTREAL, Feb. 25, 2026 ...
Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...
GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results